RaySearch Laboratories ABSTU:27R +1.56%83 Net Margin % is 18.33% as of Mar. 2026, which is 79% above its 10-year median of 10.25. GuruFocus rates STU:27R with a GF Score™ of 83/100 and a GF Value™ of €17.14 (Fairly Valued). The stock has 2 warning signs investors should review. Among 665 Healthcare Providers & Services companies, RaySearch Laboratories AB ranks better than 90.83% on this metric.
The historical rank and industry rank for RaySearch Laboratories AB's Net Margin % or its related term are showing as below:
STU:27R'
s Net Margin % Range Over the Past 10 Years
Min: -7.37 Med: 10.25 Max: 28.49
Current: 17.21
STU:27R's Net Margin % is ranked better than 90.83% of 665
companies
in the Healthcare Providers & Services industry
Industry Median: 2.89
vs STU:27R: 17.21
RaySearch Laboratories AB (STU:27R) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
RaySearch Laboratories AB Net Margin % Related Terms
RaySearch Laboratories AB Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:27R vs VEEV, BTSG, TEM: Net Margin % Comparison
For the Health Information Services subindustry, RaySearch Laboratories AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaySearch Laboratories AB Net Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, RaySearch Laboratories AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where RaySearch Laboratories AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaySearch Laboratories AB (STU:27R) has a Net Margin % of 18.33% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on RaySearch Laboratories AB and its competitors. This is 79% above median its historical median of 10.25. According to the industry distribution chart, RaySearch Laboratories AB ranks #61 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 9.2%.
Is RaySearch Laboratories AB's Net Margin % too high?
RaySearch Laboratories AB's current Net Margin % of 18.33% is 79% above median its 10-year median of 10.25. The Healthcare Providers & Services industry median Net Margin % is 2.89. RaySearch Laboratories AB's value of 18.33% is 534.3% above this industry median. Based on the distribution chart, RaySearch Laboratories AB ranks #61 out of 665 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, RaySearch Laboratories AB has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RaySearch Laboratories AB's Net Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, RaySearch Laboratories AB ranks #61 out of 665 companies for Net Margin %. This places RaySearch Laboratories AB in the top 9% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.89. RaySearch Laboratories AB's value of 18.33% is 534.3% above this benchmark. While the company's 10-year median is 10.25 vs. the industry median of 2.89, RaySearch Laboratories AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Healthcare Providers & Services company?
The median Net Margin % among Healthcare Providers & Services companies is 2.89, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaySearch Laboratories AB's current Net Margin % of 18.33% is 534.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on RaySearch Laboratories AB and its competitors. For the Healthcare Providers & Services industry, the median Net Margin % is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaySearch Laboratories AB's current Net Margin % is 18.33%, which is 79% above median its own 10-year median of 10.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaySearch Laboratories AB stock overvalued right now?
Based on GuruFocus' analysis, RaySearch Laboratories AB (STU:27R) is currently considered Fairly Valued. The stock's GF Value™ is €17.14, compared to a current price of €18.88 — trading 10.2% above its estimated fair value. The current Net Margin % is 18.33%, which is 79% above median its 10-year median of 10.25 and 534.3% above the Healthcare Providers & Services industry median of 2.89. RaySearch Laboratories AB's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For RaySearch Laboratories AB (STU:27R), the current Net Margin % is 18.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaySearch Laboratories AB (STU:27R) Overvalued in 2026?
Based on GuruFocus' analysis, RaySearch Laboratories AB stock appears to be overvalued.
The current stock price of €18.88 is trading 10.2% above its estimated GF Value™ of €17.14.
GuruFocus considers RaySearch Laboratories AB to be Fairly Valued.
Key valuation signals for STU:27R:
Net Margin %: 18.33% (79% above median its 10-year median of 10.25)
GF Value™: €17.14 vs. price of €18.88 (10.2% above fair value)
Industry Position: 534.3% above the Healthcare Providers & Services median (#61 of 665)
No single metric tells the full story. See the STU:27R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops software solutions for improved cancer treatment. The company develops and markets the RayStation treatment planning system and RayCare oncology information system to clinics all over the world and distributes products through licensing agreements with medical technology companies. Its geographic segments consist of the Americas, Asia-Pacific & Middle East, Europe, and the rest of world.
83GF Score
Get the complete analysis for STU:27R
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:27R has been successfully added to your 
